SEC Form 4 · accession 0001209191-15-005339

Clovis Oncology, Inc. · CLVS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).

Reporting owner

Officer — See Remarks

Period of report

Jan 15, 2015

Accepted (ET)

Jan 20, 2015 · 9:11 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001466301

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Jan 15, 2015	S	300	$65.00	D	181,619	D
Common Stock^F1,F2	Jan 16, 2015	S	30,524	$65.2675	D	151,095	D
Common Stock^F1,F3	Jan 16, 2015	S	49,176	$65.877	D	101,919	D

No Table II lines on this filing.

F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2014.
F2The price reported reflects the weighted average sale price. The shares of Common Stock were purchased in multiple transactions at prices ranging from $65.00 to $65.94, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3The price reported reflects the weighted average sale price. The shares of Common Stock were purchased in multiple transactions at prices ranging from $66.01 to $67.00, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Executive Vice President of Clinical and Pre-Clinical Development and Chief Medical Officer